The Experts below are selected from a list of 21 Experts worldwide ranked by ideXlab platform
T Kariya - One of the best experts on this subject based on the ideXlab platform.
-
A Comparison of the Clinical Effects of Timiperone, a New Butyrophenone Derivative, and Haloperidol on Schizophrenia Using a Double-Blind Technique
2016Co-Authors: T KariyaAbstract:The efficacy and safety of timiperone, a new Butyrophenone Derivative, in schizophrenia as compared with haloperidol were assessed in a multi-clinic double-blind controlled study in a total of206 patients. The patients were given timiperone (1·0 mgltablet) or haloperidol (1·5 mgltablet) in a daily dose of 1-3 tablets for the first day, then up to a maximum of12 tablets depending on symptoms for 12 weeks. Timiperone was found to be significantly superior to haloperidol in the final global improvement rating and in the general usefulness rating. In the over-all safety rating there were no statistically significant differences between the two drug treatments. With regard to analysis by stratification timiperone was superior to haloperidol in improving abnormal experiences such as hallucination and delusion as well as deficiency of initiative and blunted affect. From these results it is considered that timiperone could be superior to haloperidol in the treatment ofschizophrenia. at PENNSYLVANIA STATE UNIV on September 18, 2016imr.sagepub.comDownloaded from T K ariya et a
Anna D Gudmundsdottir - One of the best experts on this subject based on the ideXlab platform.
-
the effects of h bonding and sterics on the photoreactivity of a trimethyl Butyrophenone Derivative
Photochemical and Photobiological Sciences, 2012Co-Authors: Jagadis Sankaranarayanan, Michael Hawk, Vivian T Tran, Jessica L Brown, Anna D GudmundsdottirAbstract:The irradiation of ester 1 in methanol and chloroform does not yield any photoproducts, whereas the photolysis of 1 in dry argon-saturated benzene produces cyclobutanol 4, which is converted to lactone 5 by the addition of HCl. Laser-flash photolysis of ester 1 demonstrates that 1 undergoes intramolecular H-atom abstraction to form the biradical 2 (λmax ∼ 310 nm, τ = 200 ns, benzene), which intersystem crosses to photoenols, Z-3 (λmax ∼ 380 nm, τ = 30–60 μs, benzene) and E-3 (λmax ∼ 380 nm, τ = 11 ms, benzene). Density functional theory calculations were performed to support the proposed mechanism for forming cyclobutanol 4 and to explain how steric demand facilitates photoenol E-3 to form cyclobutanol 4 rather than lactone 5.
Currow, David C. - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium
'Mary Ann Liebert Inc', 2013Co-Authors: Crawford, Gregory B., Meera, Agar M., Quinn, Stephen J., Phillips Jane, Litster Caroline, Michael Natasha, Doogue Matthew, Rowett Debra, Currow, David C.Abstract:Introduction: Prescribing practice in hospice/palliative care is largely extrapolated from other areas of clinical practice, with few studies of net medication effects (benefits and harms) in hospice/palliative care to guide prescribing decisions. Hospice/palliative care patients differ in multiple ways from better studied participant groups, hence the applicability of studies in other participant groups is uncertain. Haloperidol, a Butyrophenone Derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care. Its frequent use in delirium occurs despite little evidence of the effect of antipsychotics on the untreated course of delirium. The aim of this study was to examine the immediate and short-term clinical benefits and harms of haloperidol for delirium in hospice/palliative care patients. Method: A consecutive cohort of participants from 14 centers across four countries who had haloperidol commenced for delirium were recruited. Data were collected at three time points: baseline, 48 hours (clinical benefits), and day 10 (clinical harms). Investigators were also able to report clinical harms at any time up to 14 days after it was commenced. Results: Of the 119 participants included, the average dose was 2.1mg per 24 hours; 42 of 106 (35.2%) reported benefit at 48 hours. Harm was reported in 14 of 119 (12%) at 10 days, the most frequent being somnolence (n=11) and urinary retention (n=6). Seven participants had their medication ceased due to harms (2 for somnolence and 2 for rigidity). Approximately half (55/119) were still being treated with haloperidol after 10 days. Conclusion: Overall, 1 in 3 participants gained net clinical benefit at 10 days
Dc Currow - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for delirium
'Mary Ann Liebert Inc', 2013Co-Authors: Gb Crawford, Meera, Agar M., Sj Quinn, Phillips J, Litster C, Michael N, Doogue M, Rowett D, Dc CurrowAbstract:Introduction: Prescribing practice in hospice/palliative care is largely extrapolated from other areas of clinical practice, with few studies of net medication effects (benefits and harms) in hospice/palliative care to guide prescribing decisions. Hospice/palliative care patients differ in multiple ways from better studied participant groups, hence the applicability of studies in other participant groups is uncertain. Haloperidol, a Butyrophenone Derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care. Its frequent use in delirium occurs despite little evidence of the effect of antipsychotics on the untreated course of delirium. The aim of this study was to examine the immediate and short-term clinical benefits and harms of haloperidol for delirium in hospice/palliative care patients. Method: A consecutive cohort of participants from 14 centers across four countries who had haloperidol commenced for delirium were recruited. Data were collected at three time points: baseline, 48 hours (clinical benefits), and day 10 (clinical harms). Investigators were also able to report clinical harms at any time up to 14 days after it was commenced. Results: Of the 119 participants included, the average dose was 2.1 mg per 24 hours; 42 of 106 (35.2%) reported benefit at 48 hours. Harm was reported in 14 of 119 (12%) at 10 days, the most frequent being somnolence (n=11) and urinary retention (n=6). Seven participants had their medication ceased due to harms (2 for somnolence and 2 for rigidity). Approximately half (55/119) were still being treated with haloperidol after 10 days. Conclusion: Overall, 1 in 3 participants gained net clinical benefit at 10 days. © Copyright 2013, Mary Ann Liebert, Inc. 2013
Meera, Agar M. - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium
'Mary Ann Liebert Inc', 2013Co-Authors: Crawford, Gregory B., Meera, Agar M., Quinn, Stephen J., Phillips Jane, Litster Caroline, Michael Natasha, Doogue Matthew, Rowett Debra, Currow, David C.Abstract:Introduction: Prescribing practice in hospice/palliative care is largely extrapolated from other areas of clinical practice, with few studies of net medication effects (benefits and harms) in hospice/palliative care to guide prescribing decisions. Hospice/palliative care patients differ in multiple ways from better studied participant groups, hence the applicability of studies in other participant groups is uncertain. Haloperidol, a Butyrophenone Derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care. Its frequent use in delirium occurs despite little evidence of the effect of antipsychotics on the untreated course of delirium. The aim of this study was to examine the immediate and short-term clinical benefits and harms of haloperidol for delirium in hospice/palliative care patients. Method: A consecutive cohort of participants from 14 centers across four countries who had haloperidol commenced for delirium were recruited. Data were collected at three time points: baseline, 48 hours (clinical benefits), and day 10 (clinical harms). Investigators were also able to report clinical harms at any time up to 14 days after it was commenced. Results: Of the 119 participants included, the average dose was 2.1mg per 24 hours; 42 of 106 (35.2%) reported benefit at 48 hours. Harm was reported in 14 of 119 (12%) at 10 days, the most frequent being somnolence (n=11) and urinary retention (n=6). Seven participants had their medication ceased due to harms (2 for somnolence and 2 for rigidity). Approximately half (55/119) were still being treated with haloperidol after 10 days. Conclusion: Overall, 1 in 3 participants gained net clinical benefit at 10 days
-
Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for delirium
'Mary Ann Liebert Inc', 2013Co-Authors: Gb Crawford, Meera, Agar M., Sj Quinn, Phillips J, Litster C, Michael N, Doogue M, Rowett D, Dc CurrowAbstract:Introduction: Prescribing practice in hospice/palliative care is largely extrapolated from other areas of clinical practice, with few studies of net medication effects (benefits and harms) in hospice/palliative care to guide prescribing decisions. Hospice/palliative care patients differ in multiple ways from better studied participant groups, hence the applicability of studies in other participant groups is uncertain. Haloperidol, a Butyrophenone Derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care. Its frequent use in delirium occurs despite little evidence of the effect of antipsychotics on the untreated course of delirium. The aim of this study was to examine the immediate and short-term clinical benefits and harms of haloperidol for delirium in hospice/palliative care patients. Method: A consecutive cohort of participants from 14 centers across four countries who had haloperidol commenced for delirium were recruited. Data were collected at three time points: baseline, 48 hours (clinical benefits), and day 10 (clinical harms). Investigators were also able to report clinical harms at any time up to 14 days after it was commenced. Results: Of the 119 participants included, the average dose was 2.1 mg per 24 hours; 42 of 106 (35.2%) reported benefit at 48 hours. Harm was reported in 14 of 119 (12%) at 10 days, the most frequent being somnolence (n=11) and urinary retention (n=6). Seven participants had their medication ceased due to harms (2 for somnolence and 2 for rigidity). Approximately half (55/119) were still being treated with haloperidol after 10 days. Conclusion: Overall, 1 in 3 participants gained net clinical benefit at 10 days. © Copyright 2013, Mary Ann Liebert, Inc. 2013
